Loading...
Market
Total milestone payments made by Novartis to Baiyu by end of 2025?
3
Resolution / Starting Odds
Less than $100 million • 25%
$100 million to $300 million • 25%
$300 million to $500 million • 25%
More than $500 million • 25%
Financial disclosures from Novartis or Chengdu Baiyu Pharmaceutical
Story
Sweden’s Novartis Secures Global Rights for Baiyu's Cancer Drug with $70M Upfront, $1.1B Milestone
Oct 18, 2024, 11:07 AM
Novartis has entered into a significant agreement with Chengdu Baiyu Pharmaceutical, paying $70 million upfront and potentially up to $1.1 billion in milestone payments for a small molecule cancer candidate. This deal grants Novartis exclusive global rights to Baiyu's innovative cancer drug. The collaboration aims to enhance Novartis' portfolio of cancer treatments, reflecting the growing acceptance and integration of Chinese research in the global pharmaceutical landscape. Additionally, Novartis received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Kisqali® to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.
View original story
Similar markets
Up to $150 million • 25%
$150 million to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Less than €100 million • 25%
€100 million to €200 million • 25%
€200 million to €300 million • 25%
More than €300 million • 25%
No milestone payments • 25%
Up to $500 million • 25%
$500 million to $1 billion • 25%
Over $1 billion • 25%
None • 25%
Up to $100M • 25%
$100M to $200M • 25%
Over $200M • 25%
Less than €100 million • 33%
Between €100 million and €500 million • 33%
More than €500 million • 33%
Yes • 50%
No • 50%
None • 25%
Up to $200 million • 25%
$200 million to $600 million • 25%
Above $600 million • 25%
Milestone 1 • 25%
Milestone 2 • 25%
Milestone 3 • 25%
No milestone achieved • 25%
